Abstract:Huntington’s Disease (HD) is a neurodegenerative disorder, part of the nine identified inherited polyglutamine (polyQ) diseases. Most commonly, HD pathophysiology manifests in middle-aged adults with symptoms including progressive loss of motor control, cognitive decline, and psychiatric disturbances. Associated with the pathophysiology of HD is the formation of insoluble fragments of the huntingtin protein (htt) that tend to aggregate in the nucleus and cytoplasm of neurons. To track both the intracellular progression of the aggregation phenotype as well as the physiological deficits associated with mutant htt, two constructs of human HTT were expressed with varying polyQ lengths, non-pathogenic-htt (Q15, NP-htt) and pathogenic-htt (Q138, P-htt), with an N-terminal RFP tag for visualization. P-htt aggregates accumulate in the ventral nerve cord cell bodies as early as 24 hours post hatching and significant aggregates form in the segmental nerve branches at 48 hours post hatching. Organelle trafficking up-and downstream of aggregates formed in motor neurons showed severe deficits in trafficking dynamics. To explore putative downstream deficits of htt aggregation, ultrastructural changes of presynaptic motor neurons and muscles were assessed, but no significant effects were observed. However, the force and kinetics of muscle contractions were severely affected in P-htt animals, reminiscent of human chorea. Reduced muscle force production translated to altered locomotory behavior. A novel HD aggregation model was established to track htt aggregation throughout adulthood in the wing, showing similar aggregation patterns with larvae. Expressing P-htt in the adult nervous system resulted in significantly reduced lifespan, which could be partially rescued by feeding flies the mTOR inhibitor rapamycin. These findings advance our understanding of htt aggregate progression as well the downstream physiological impacts on the nervous system and peripheral tissues.

A Striatal-Enriched Intronic GPCR Modulates Huntingtin Levels and Toxicity

HAP40 is a conserved central regulator of Huntingtin and a specific modulator of mutant Huntingtin toxicity

GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington’s Disease-Related Phenotypes

Protective role of downregulation in Huntington’s Disease models

Region-specific pro-survival signaling and global neuronal protection by wild-type Huntingtin

HAP40 modulates mutant Huntingtin aggregation and toxicity in Huntington's disease mice

Regulation of P-glycoprotein expression in brain capillaries in Huntington’s disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone

Inhibitor-based modulation of huntingtin aggregation mechanisms reduces fibril toxicity

Essential sequence of the N-terminal cytoplasmic localization-related domain of huntingtin and its effect on huntingtin aggregates

Mutant Huntingtin stalls ribosomes and represses protein synthesis in a cellular model of Huntington disease

TRIM37 is a primate-specific E3 ligase for Huntingtin and accounts for the striatal degeneration in Huntington's disease

Accumulation of Endogenous Mutant Huntingtin in Astrocytes Exacerbates Neuropathology of Huntington Disease in Mice

HAP40 is a conserved central regulator of Huntingtin and a potential modulator of Huntington's disease pathogenesis

Downregulation of Glial Genes Involved in Synaptic Function Mitigates Huntington's Disease Pathogenesis

Htt Cag Repeat Expansion Confers Pleiotropic Gains Of Mutant Huntingtin Function In Chromatin Regulation

CGS21680 Attenuates Symptoms of Huntington's Disease in a Transgenic Mouse Model

Pathological Cell-Cell Interactions Elicited by a Neuropathogenic Form of Mutant Huntingtin Contribute to Cortical Pathogenesis in HD Mice

Multi-epitope immunocapture of huntingtin reveals striatum-selective molecular signatures

Developmental and physiological impacts of pathogenic human huntingtin protein in the nervous system

Integrated analysis on transcriptome and behaviors defines HTT repeat-dependent network modules in Huntington's disease

PRMT5 is required for full-length expression by repressing multiple proximal intronic polyadenylation sites